摘要
目的探讨托吡酯辅助治疗氯氮平所致糖脂代谢紊乱的疗效和安全性。方法将72例稳定服用治疗剂量或维持剂量的氯氮平患者,随机分为两组,一组合并托吡酯治疗(研究组),另一组单用氯氮平治疗(对照组)。观察治疗6个月,定期测体重、腰围、血糖、血脂、UKU不良反应量表。对研究组与对照组的临床资料进行比较。结果 6个月末两组的血糖水平有统计学意义(t=-2.54,P<0.05),甘油三酯和总胆固醇两组相比有统计学差异(t=-2.15,-2.54;P<0.05)。两组不良反应的比较经t检验差异无统计学意义(t=1.463,P>0.05)。结论托吡酯辅助治疗氯氮平所致糖脂代谢紊乱疗效好、安全性高。
Objective To Explore efficacy and safety of topiramate in adjuvant treating glucose and lipid metabolism disorders caused by clozapine.Methods With prospective parallel controlled method,72 patients of stable therapeutic dose or maintenance dose of clozapine were randomly divided into two groups,and a combination of topiramate treatment（study group）,another group of clozapine treatment alone（control group）.these two groups were observed for 6 months,regularly measured weight,waist circumference,blood glucose,blood lipids,UKU adverse response scale.Results There were significant differences in blood glucose level（t=-2.54,P0.05）,triglycerides（t=-2.15,P0.05）and total cholesterol（t=-2.54,P0.05） between two groups at 6 end of the month.there was no significant differennce in adverse reactions（t=1.463,P0.05）.Conclusion Topiramate is efficacy and high safety in the adjuvant treatment of glucose and lipid metabolic disorders caused by clozapine.
出处
《中国健康心理学杂志》
2011年第10期1157-1159,共3页
China Journal of Health Psychology
基金
保定市科学技术发展与规划项目(编号:08ZF0047)
关键词
抗精神病药物
氯氮平
托吡酯
体重
糖脂代谢紊乱
Antipsychotics
Clozapine
Topiramate
Weight
Glucose and lipid metabolism disorders
